NCT00494767View on ClinicalTrials.gov

Investigation Of Weight Loss And Body Composition Changes After Dosing With Either Placebo Or One Of Two Active Drugs

PHASE1CompletedINTERVENTIONAL
Enrollment

27

Participants

Timeline

Start Date

September 29, 2006

Primary Completion Date

June 7, 2007

Study Completion Date

June 7, 2007

Conditions
Diabetes Mellitus, Type 2Obesity
Interventions
DRUG

GW869682

GW869682 tablet with a dose strength of 250 mg will be available for subjects

DRUG

GSK189075

GSK189075 tablet with a dose strength of 250 mg will be available for subjects

DRUG

GSK189075-Placebo

Placebo tablets to match GSK189075 250 mg will be available for subjects

DRUG

GW869682-Placebo

Placebo tablets to match GW869682 250 mg will be available for subjects

Trial Locations (1)

CB2 2GG

GSK Investigational Site, Cambridge

Sponsors

Lead Sponsor

GlaxoSmithKline
All Listed Sponsors
lead

GlaxoSmithKline

INDUSTRY